[Diagnostic value of a simple scoring system for the diagnosis and treatment of non-emergency small bowel obstruction].

In order to improve the diagnostic accuracy and treatment strategy for small bowel obstruction, we developed a non-emergency small bowel obstruction scoring system (0-4). We performed a retrospective analysis on 94 patients diagnosed with mechanical small bowel obstruction at our hospital. Anterior adhesion, small bowel feces sign, scoring system, and the usefulness of small bowel feces subtypes were examined. When the non-emergency small bowel obstruction scores 3-4, 99% were non-emergency obstructions, with the exclusion of strangulated small bowel obstruction. On the contrary, when the non-emergency small bowel obstruction scores 0-1, 47.5% were strangulated small bowel obstruction. As the effectiveness of withholding food and fluids (NPO) or short tube is high (about 70%) when small bowel feces are dry, placing a long tube may not be needed.

Abdominal aortic aneurysmal and endovascular device infection with iliopsoas abscess caused by Mycobacterium bovis as a complication of intravesical bacillus Calmette-Guérin therapy.

Vascular complications after the intravesical instillation of Bacillus Calmette-Guérin (BCG) therapy are extremely rare. We experienced a case of abdominal aortic aneurysmal infection excluded by a stent graft with an iliopsoas abscess after intravesical instillation of BCG therapy that required reoperation. Five years ago, an 81-year-old man was diagnosed with transitional cell carcinoma of the bladder. After transurethral resection of the bladder tumor and intravesical BCG therapy, a radical cystectomy was performed. Twenty-four months after intravesical BCG therapy, follow-up an abdominal computed tomographic (CT) scan revealed an aortic abdominal aneurysm. Endovascular aneurysm repair was performed, and the aneurysm was excluded postoperatively. Thirty months after the endovascular aneurysm repair (and 54 months after intravesical BCG therapy), a follow-up abdominal CT revealed a low-density area in the right iliopsoas muscle that formed a fistula to the excluded aneurysm. We performed CT-guided iliopsoas abscess drainage and collected yellow pus. Polymerase chain reaction analysis revealed that the pus was positive for Mycobacterium tuberculosis complex. The patient was diagnosed with abdominal aortic aneurysmal infection associated with iliopsoas abscess caused by Mycobacterium bovis, and surgery was performed. We performed an extra-anatomical bypass and removed the stent graft with debridement. When the aneurysmal wall was incised and resected, yellow pus surrounded the stent graft. In addition, a large fistula was present between the right posterolateral aortic aneurysmal wall and the iliopsoas abscess cavity. After the operation, the histopathological examination of excised abdominal aortic aneurysmal wall tissue revealed an epithelioid granuloma with caseous necrosis involving multinucleated giant cells, indicating M tuberculosis complex infection. Although the intravesical instillation of BCG therapy is considered safe, complications resulting from vascular infections can arise in extremely rare cases. The complication described in this case report emphasizes the need to cautiously select treatment for a mycotic aortic aneurysm after intravesical instillation of BCG therapy.

[Efficacy of combined local therapy especially with hepatic arterial infusion for liver metastasis from gastric cancer].

Herein, we report four cases of a single liver metastasis after gastric cancer resection. Initially, we chose to perform hepatic arterial infusion( HAI) with high-dose 5-fluorouracil( 5-FU)( 6,000 mg/week) or weekly 500-750 mg of 5-FU. Three patients showed a partial response (PR) and one patient showed no change (NC). Therefore, we performed hepatectomy or radiofrequency ablation( RFA) 300-350 days after HAI. All four patients received postoperative HAI. Two patients survived without recurrence for 12 and 21 months. One patient developed prostate cancer but survived for 22 months as an outpatient. Finally, one patient experienced recurrence in the residual liver, but at a site not supplied by the hepatic artery. This patient survived for 36 months as an outpatient. In conclusion, HAI, liver resection, and RFA are effective in the management of single liver metastasis from gastric cancer.

In vivo evaluation of cisplatin-loaded superabsorbent polymer microspheres for use in chemoembolization of VX2 liver tumors.

PURPOSE: To investigate the pharmacokinetics and efficacy of chemoembolization with a cisplatin-loaded superabsorbent polymer (SAP) suspension in a rabbit model with transplanted liver VX2 tumors. MATERIALS AND METHODS: VX2 tumors were implanted into the left lobe of the liver in eight rabbits. Embolization of the proper hepatic artery was performed with cisplatin-loaded or unloaded SAP. In the cisplatin-loaded SAP group (n = 4), 5 mg of SAP (106-150 µm) loading 2.35 mg of cisplatin and 0.5 mL of ionic contrast material (ioxaglic acid 320 mgI/mL) was injected into the proper hepatic artery. In the control group (hepatic arterial infusion [HAI] + SAP; n = 4), 5 mg of SAP loading 0.5 mL of ioxaglic acid alone was injected after a bolus infusion of an equivalent amount of cisplatin. Sequential change of the plasma platinum concentration within the first 24 hours was measured. Blood sampling and histopathologic examination were performed at 1-week follow-up. Magnetic resonance (MR) images were used to calculate the growth rate of the VX2 tumor. RESULTS: All animals underwent successful embolization. Both total and free plasma platinum mean concentrations within the first 24 hours remained lower in the cisplatin-loaded SAP group, although without statistical significance (P > .05). The mean tumor growth rate was significantly lower in the cisplatin-loaded SAP group than the control group (20% vs 116%; P = .049). Histopathologic examination revealed coagulative necrosis to nontumorous liver parenchyma in two rabbits in the cisplatin-loaded SAP group, although no deaths occurred. CONCLUSIONS: These results suggested that chemoembolization with cisplatin-loaded SAP was a safe and tolerable treatment and was more effective in suppressing the tumor growth.

Transarterial chemoembolization with cisplatin as second-line treatment for hepatocellular carcinoma unresponsive to chemoembolization with epirubicin-Lipiodol emulsion.

PURPOSE: The purpose of this retrospective study was to investigate the efficacy of transarterial chemoembolization (TACE) using cisplatin as a second-line treatment for advanced hepatocellular carcinoma (HCC) unresponsive to TACE using epirubicin-Lipiodol emulsion at our institution. MATERIALS AND METHODS: Between January 2006 and March 2009, 51 patients with unresectable HCC underwent TACE using cisplatin. All patients had shown persistent viable tumor or tumor progression after at least 2 sessions of TACE using epirubicin-Lipiodol emulsion. TACE procedures consisted of arterial injection of a mixture of Lipiodol and cisplatin (30-100 mg [mean 57 ± 21]) (n = 29) or arterial infusion of cisplatin (30-100 mg [mean 87 ± 19]) solution (n = 22) followed by injection of 1-mm porous gelatin particles. Early tumor response was assessed by contrast-enhanced computed tomography (CT) according to Response Evaluation Criteria in Solid Tumors (RECIST) and European Association for the Study of the Liver (EASL) criteria. Overall survival and progression-free survival was calculated using the Kaplan-Meier method. Toxicity was assessed according to NCI-CTCAE version 3 criteria. RESULTS: Response rates were 11.8 and 27.5% by RECIST and EASL criteria, respectively. Overall survival rates were 61.9, 48.2, and 28.9% at 1, 2, and 3 years, respectively, and the median survival time was 15.4 months. Progression-free survival rate was 35.2% at 1 year, and median progression-free survival time was 3.1 months. No major complications were observed, and the occurrence of postembolization syndrome was minimal. Grade 3 to 4 toxicities included thrombocytopenia (5.8%), increased aspartate aminotransferase (AST) level (35.3%), and increased alanine aminotransferase (ALT) level (23.5%). CONCLUSION: Switching the TACE anticancer drug from epirubicin to cisplatin might be the feasible option for advanced HCC, even when considered resistant to the initial form of TACE.

Usefulness of contrast-enhanced three-dimensional MR angiography using time-resolved imaging of contrast kinetics applied to description of Extracranial Arteriovenous Malformations: initial experience.

PURPOSE: The purpose of this study was to evaluate the usefulness of contrast-enhanced three-dimensional MR angiography using time-resolved imaging of contrast kinetics (TRICKS-MRA) to demonstrate extracranial arteriovenous malformations (E-AVMs). MATERIALS AND METHODS: TRICKS-MRA was performed in 33 patients (adults; n = 30, children; n = 3) with E-AVMs. Four different scan protocols were arranged based on the size of E-AVM, and serial images were acquired from the start of contrast injection with a time frame ranging from 1.2 to 7.1s. Demonstration of feeding arteries and drainage veins, and the extent of nidus was qualitatively graded using a three-point scale. In sixteen patients who underwent DSA 3 days to 15 months after TRICKS-MRA, the comparability of TRICKS-MRA to DSA was evaluated using a three-point scale. In each category, score of 3 or excellent was defined as the positive result. RESULTS: Demonstration of the feeding arteries, the drainage veins, and the extent of nidus were graded as excellent in 68%, 65%, and 58% of the patients, respectively. Comparability of TRICKS-MRA to DSA was excellent in 75%, 88%, and 88% of the sixteen patients who underwent DSA. CONCLUSION: TRICKS-MRA is a feasible and useful vascular imaging technique to provide time-resolved analysis of angioarchitecture of E-AVMs.

Abdominal multi-detector row CT: effectiveness of determining contrast medium dose on basis of body surface area.

PURPOSE: To investigate the validity of determining the contrast medium dose based on body surface area (BSA) for the abdominal contrast-enhanced multi-detector row CT comparing with determining based on body weight (BW). MATERIALS AND METHODS: Institutional review committee approval was obtained. In this retrospective study, 191 patients those underwent abdominal contrast-enhanced multi-detector row CT were enrolled. All patients received 96 mL of 320 mg I/mL contrast medium at the rate of 3.2 mL. The iodine dose required to enhance 1 HU of the aorta at the arterial phase and that of liver parenchyma at portal venous phase per BSA were calculated (EUBSA) and evaluated the relationship with BSA. Those per BW were also calculated (EUBW) and evaluated. Estimated enhancement values (EEVs) of the aorta and liver parenchyma with two protocols for dose decision based on BSA and BW were calculated and patient-to-patient variability was compared between two protocols using the Levene test. RESULTS: The mean of EUBSA and EUBW were 0.0621 g I/m2/HU and 0.00178 g I/kg/HU for the aorta, and 0.342 g I/m2/HU and 0.00978 g I/kg/HU for the liver parenchyma, respectively. In the aortic enhancement, EUBSA was almost constant regardless of BSA, and the mean absolute deviation of the EEV with the BSA protocol was significantly lower than that with the BW protocol (P<.001), although there was no significant difference between two protocols in the hepatic parenchymal enhancement (P=.92). CONCLUSION: For the aortic enhancement, determining the contrast medium dose based on BSA was considered to improve patient-to-patient enhancement variability.

Correlations between aorto-popliteal bolus transit speed and aortic and popliteal bolus transit time during CT angiography of aortoiliac and lower extremity arteries.

PURPOSE: The purpose of this study was to investigate correlations between the aorto-popliteal bolus transit speed and aortic and popliteal bolus transit time in order to evaluate the possibility for prediction of bolus transit speed by single test injection technique. MATERIALS AND METHODS: Approval was obtained from our institutional review board for this study, which included 42 patients, from all of whom written informed consent was obtained. Low-dose serial CT scanning after injection of 12 ml contrast material (300 mg/ml) at a rate of 3 ml/s followed by saline flush was performed twice, first at the level of the upper abdomen and second at the level of the knee joint. The times needed to reach peak enhancement of the upper abdominal aorta (T-aorta) and bilateral popliteal arteries (T-popliteal) were obtained, and aorto-popliteal bolus transit speeds between the abdominal aorta and popliteal arteries were calculated. ABI was recorded for the bilateral feet. The Pearson's product-moment correlation coefficient was used to investigate the correlation between the bolus transit speed and T-aorta, T-popliteal, ABI, and patient age. RESULT: The respective correlation coefficients for bolus transit speed on the one hand and T-aorta, T-popliteal, ABI, patient age on the other were -0.50, -0.84, 0.36, and -0.52. CONCLUSION: The time to peak enhancement for popliteal arteries showed the strongest correlation with aorto-popliteal bolus transit speeds, and was considered to be the most accurate predictor for aorto-popliteal bolus transit speeds.

Uterine tumors: comparison of 3D versus 2D T2-weighted turbo spin-echo MR imaging at 3.0 T--initial experience.

PURPOSE: To compare a three-dimensional (3D) T2-weighted turbo spin-echo (TSE) magnetic resonance (MR) sequence (VISTA; Philips Medical Systems, Best, the Netherlands) with a two-dimensional (2D) T2-weighted TSE sequence in terms of image quality, signal intensity (SI) difference ratios, conspicuity, and staging of uterine tumors. MATERIALS AND METHODS: This retrospective study was approved by the institutional review board, and informed consent was waived. Sixty-one women (mean age, 53.0 years ± 13.7 [standard deviation]; range, 30-87 years) with cervical carcinoma (n = 28), endometrial carcinoma (n = 21), or leiomyoma (n = 30) of the uterus were included. Patients underwent T2-weighted MR imaging at 3 T with both 1-mm-thick 3D and 5-mm-thick 2D T2-weighted TSE sequences. Three-dimensional T2-weighted TSE images were reconstructed at 5-mm thickness with the aid of a workstation. Quantitative analyses of signal-to-noise ratio (SNR) and SI difference ratios between tumors and other tissues and qualitative analyses of image quality and tissue conspicuity were performed. Two radiologists independently assessed local-regional staging for carcinomas. Quantitative values, qualitative scores, and tumor staging were analyzed by using the paired t test, Wilcoxon signed rank test, and McNemar test, respectively. RESULTS: Mean myometrial SNR was higher on 3D than 2D images (14.3 vs 9.8; P < .0001). Mean SI difference ratios between cervical (0.45 vs 0.34; P < .0001) or endometrial (0.46 vs 0.40; P = .044) carcinomas and gluteal muscle were higher on 3D images, but those between leiomyoma and myometrium (0.33 vs 0.43; P < .0001) were lower than those on 2D images. Image quality (P = .0004) and carcinoma conspicuity (P < .0005) were superior with the 3D T2-weighted TSE sequence. Although multiplanar reconstruction of 3D T2-weighted TSE images was useful for staging in one case, there were no significant differences between 3D and 2D T2-weighted TSE imaging in accuracy of staging for the two readers for cervical or endometrial carcinoma. CONCLUSION: The 3D T2-weighted TSE sequence showed certain advantages over the 2D T2-weighted TSE sequence, and it has the potential to improve the performance of MR imaging for the evaluation of uterine carcinoma.

Comparative study of the diagnostic ability of magnetic resonance imaging and multidetector row computed tomography for anomalous pancreaticobiliary ductal junction.

OBJECTIVE: To compare the diagnostic performance of magnetic resonance (MR) imaging and multidetector row computed tomography (MDCT) for an anomalous pancreaticobiliary ductal junction (PBJ). METHODS: This study included 26 patients who underwent MR imaging, MDCT, and endoscopic retrograde cholangiopancreatography. Seventeen of the patients were diagnosed by endoscopic retrograde cholangiopancreatography as having an anomalous PBJ. Three radiologists independently reviewed MR images alone, contrast-enhanced CT images alone, and MR images and CT images combined. Receiver operating characteristic curve analysis was used to compare diagnostic capabilities. RESULTS: The mean area under the receiver operating characteristic curve (Az [95% confidence interval]) was 0.75 (0.73-0.77) for MR imaging alone, 0.79 (0.70-0.89) for CT alone, and 0.84 (0.82-0.86) for the 2 modalities combined. Only between the combination and MR imaging alone was there significant difference in Az value (P < 0.05). CONCLUSIONS: The diagnostic performance of MR imaging and MDCT was equivalent for an anomalous PBJ. The addition of MDCT to MR imaging improved the diagnostic performance.

Hepatocellular carcinoma: hepatocyte-selective enhancement at gadoxetic acid-enhanced MR imaging--correlation with expression of sinusoidal and canalicular transporters and bile accumulation.

PURPOSE: To investigate the mechanism of enhancement of hepatocellular carcinoma (HCC) on gadoxetic acid-enhanced hepatobiliary phase magnetic resonance (MR) images and to characterize HCC thus enhanced. MATERIALS AND METHODS: This retrospective study was approved by the institutional review board, and patient informed consent for research use of the resected specimen was obtained. MR images in 25 patients (20 men, five women; mean age, 68 years; range, 49-82 years) with 27 resected hypervascular HCCs (one well, 13 moderately, 13 poorly differentiated) that demonstrated hepatocyte-selective enhancement on gadoxetic acid-enhanced MR images, were quantitatively studied, and findings were correlated with results of immunohistochemical staining for a sinusoidal transporter, organic anion transporting polypeptide (OATP) 1B1 (OATP1B1) and/or OATP1B3 (OATP1B1 and/or -1B3), and a canalicular transporter, multidrug resistance-associated protein 2 (MRP2), and also with bile accumulation in tumors. Statistical analysis was performed with the Student t test and Scheffé post hoc test. RESULTS: Combined with positive OATP1B1 and/or -1B3 expression (O+), two patterns of MRP2 expression contributed to high enhancement: decreased expression (M-, n = 3) and increased expression at the luminal membrane of pseudoglands (M+[P], n = 3). Nodules without OATP1B1 and/or -1B3 expression (O-, n = 13) and nodules with O+ associated with increased MRP2 expression only at the canaliculi (M+[C], n = 8) induced significantly lower enhancement than those with the two expression patterns described before (O+/M- group vs O- group, P = .002; O+/M- group vs O+/M+[C] group, P = .047; O+/M+[P] group vs O- group, P < .001; O+/M+[P] group vs O+/M+[C] group, P < .001). Nodules with bile pigment (n = 12) showed significantly higher enhancement (P = .004); all five nodules (one well differentiated HCC, four moderately differentiated HCCs), which were enhanced more than adjacent liver parenchyma, contained bile pigment. CONCLUSION: High hepatocyte-selective enhancement is induced by expression patterns of transporters, which may result in accumulation of gadoxetic acid in cytoplasm of tumor cells or in lumina of pseudoglands. An HCC with gadoxetic acid enhancement is characterized by bile accumulation in tumors.

In vitro characterization of cisplatin-loaded superabsorbent polymer microspheres designed for chemoembolization.

PURPOSE: To find appropriate contrast media to load cisplatin into superabsorbent polymer (SAP) and to analyze the absorption and elution kinetics of cisplatin to and from SAP. MATERIALS AND METHODS: Three contrast media-ioxaglic acid 320 mg/mL, iohexol 300 mg/mL, and iopamidol 300 mg/mL-were tested for solubility of a new highly soluble cisplatin powder. The appropriate concentrations of cisplatin were predetermined according to the solubility in each contrast medium. For each concentration, we assessed the cisplatin elution kinetics with an atomic absorption spectrophotometer. The SAP particle diameters (106-150 microm dry size) before and after drug elution were also measured. RESULTS: The concentrations of cisplatin were predetermined as 2.5 mg/mL in ioxaglic acid, 2.5 mg/mL in iohexol, and 5.0 mg/mL in iohexol. At these concentrations, 100 mg of SAP carried 5 mg, 25 mg, and 50 mg of cisplatin dissolved in ioxaglic acid (2.5 mg/mL) and iohexol (2.5 mg/mL and 5.0 mg/mL), respectively. Cisplatin-loaded SAP in ioxaglic acid and iohexol exhibited similar elution profiles, with cisplatin fractions of 15%, 40%, 70%, and 95% at 1, 3, 6, and 24 hours, respectively. By drug elution, the mean particle diameter changed from 0.31 mm to 0.61 mm in ioxaglic acid (2.5 mg/mL), from 0.54 mm to 0.60 mm in iohexol 2.5 mg/mL, and from 0.63 mm to 0.59 mm in iohexol 5.0 mg/mL. CONCLUSIONS: SAP was confirmed to absorb and elute cisplatin within 24 hours. When mixed with iohexol, SAP carried a ten times larger dose of cisplatin and expanded twice as large as when mixed with ioxaglic acid. Cisplatin-loaded SAP may have potential as a drug delivery system for the clinical treatment of liver tumors.

Differential diagnosis between metastatic tumors and nonsolid benign lesions of the liver using ferucarbotran-enhanced MR imaging.

PURPOSE: To evaluate ability of ferucarbotran-enhanced MR imaging (MRI) in differentiating metastases from nonsolid benign lesions of the liver according to signal-intensity characteristics. MATERIALS AND METHODS: Sixty-six consecutive patients, who had 138 focal hepatic lesions (26 cysts, 11 hemangiomas, and 101 metastases), underwent ferucarbotran-enhanced MRI. The signal-intensity pattern of each kind of lesion relative to the liver parenchyma on ferucarbotran-enhanced T2* and heavily T1-weighted gradient-echo images were assessed and categorized into the following three categories: high-intensity and iso-intensity, respectively (category A), high and low (category B), and iso- and low-intensity (category C). For category B, lesions were subdivided into two groups based on single-shot half-Fourier RARE images: category B1 (not significantly high-intensity) and category B2 (significantly high-intensity). RESULTS: Category A had 11 hemangiomas and 2 metastatic tumors, category B1 had 97 metastatic tumors, category B2 had 2 metastatic tumors and 9 cysts, and category C had 17 cysts. When a tumor with a signal intensity of category A was considered to be hemangioma, category B1 metastasis, and category B2 and C cyst, the diagnostic accuracy for differentiating these lesions was 97% (134/138). CONCLUSION: The combination of signal-intensity pattern on ferucarbotran-enhanced T2*- and heavily T1-weighted gradient-echo MRI has ability to differentiate liver metastases from nonsolid benign lesions. However, T2-weighted single-shot half-Fourier RARE imaging should also be employed to achieve better performance.

Salvage cystic duct anastomosis using a magnetic compression technique for incomplete bile duct reconstruction in living donor liver transplantation.

In living donor liver transplantation (LDLT), bile duct reconstruction is often technically demanding due to the frequently anomalous anatomy of the bile duct, as well as the high incidence of biliary complications. A bile duct branch may also be accidentally left without anastomosis at the time of LDLT and found to be obstructed after surgery. Surgical revision for such cases is sometimes not feasible because of the invasiveness of the procedure. We report a case in which a bile duct branch was intentionally left without anastomosis and was later successfully anastomosed to the cystic duct stump using a magnetic compression anastomosis (MCA) technique. A combination of the MCA technique and cystic duct anastomosis is life-saving in certain situations and should be considered as the treatment of choice.

MR cholangiopancreatography at 3.0 T: intraindividual comparative study with MR cholangiopancreatography at 1.5 T for clinical patients.

OBJECTIVES: To prospectively evaluate the image quality and diagnostic accuracy of magnetic resonance cholangiopancreatography (MRCP) at 3.0 T compared with that at 1.5 T used for patients. MATERIALS AND METHODS: This study was approved by our institutional review board, and informed consent was obtained from all patients. Three-dimensional MRCP with both a 1.5-T system and a 3.0-T system was administered to 33 consecutive patients suspected of having biliary and/or pancreatic diseases. For 3-dimensional MRCP imaging, a respiratory-triggered Fast Recovery Fast Spin Echo sequence with the parallel imaging technique was used for both systems. The spatial resolution at 1.5 T was matched to that at 3.0 T, and matrix size was 512 x 160, field of view (FOV) 36 x 36 cm, slice thickness 2 mm, and the number of slices ranged from 44 to 54. Repetition time varied according to the patients' respiratory cycles, which ranged from 3000 milliseconds to 6000 milliseconds, and effective echo time, ranging from 391 milliseconds to 482 milliseconds, was automatically determined by the systems. Contrast of imaging of the common bile duct versus that of the periductal tissue was quantitatively evaluated. The image quality for homogeneity of signal intensity, image noise, susceptibility artifacts, and overall imaging quality and diagnostic accuracy for stenoses of bile and main pancreatic ducts and for pancreatic cystic lesions were qualitatively evaluated. The results for 1.5- and 3.0-T were then compared statistically, by using the paired t test for quantitative evaluation of contrast between the common bile duct and the periductal tissue, the Wilcoxon signed rank test for visual evaluation of the image quality, and the McNemar chi2 test for evaluation of sensitivity and specificity for diagnostic purposes. A P value of less than 0.05 was considered to indicate a statistically significant difference. RESULTS: Contrast of the common bile duct versus that of the periductal tissue at 3.0 T was superior to that at 1.5 T (P < 0.001). In the visual evaluation, image quality at 3.0 T was superior to that at 1.5 T for evaluation of image noise (P < 0.001), overall image quality (P < 0.001), and delineation of intrahepatic bile ducts (P < 0.01) and the main pancreatic duct (P < 0.05), whereas there were no significant differences in homogeneity of signal intensity and in susceptibility artifacts. The diagnostic accuracy for 3.0 T was approximately equivalent to that for 1.5 T. CONCLUSION: Our results for patients with biliary and pancreatic diseases demonstrate a marked improvement in contrast of the common bile duct versus that of the periductal tissue and image quality including image noise at 3.0 T compared by 1.5 T when identical spatial resolution configuration were used. The results suggest that 3.0 T may allow higher spatial resolution and offer promise for improved diagnosis in MRCP, although further investigations using optimize scan parameters will be needed before its full potential can be achieved.

MR imaging of endometrial carcinoma for preoperative staging at 3.0 T: comparison with imaging at 1.5 T.

PURPOSE: To prospectively compare magnetic resonance imaging (MRI) at 3.0 T and 1.5 T in the same patients for preoperative evaluation of endometrial carcinoma. MATERIALS AND METHODS: Thirty consecutive patients with endometrial carcinoma underwent MRI at both 3.0 T and 1.5 T as well as surgery. Quantitative and qualitative analyses were performed. Two radiologists independently evaluated images. MR findings were compared with surgicopathologic findings. RESULTS: Image homogeneity of T2-weighted images at 3.0 T was significantly inferior to that at 1.5 T (P = 0.007). The scores of image homogeneity and susceptibility artifacts were not significantly different between 3.0 T gadolinium-enhanced imaging and 1.5 T imaging (P = 0.09 and 0.36). Kappa statistics showed good interobserver agreement between the two radiologists for local-regional staging on T2-weighted images (kappa>0.6). The area under the receiver operating characteristic curve (Az) values for T2-weighted imaging in terms of myometrial invasion, cervical invasion, and lymph node metastases were 0.88 (3.0 T) versus 0.91 (1.5 T), 0.84 versus 0.83, and 0.94 versus 0.95 for reader 1, respectively. There were no significant differences between imaging at 3.0 T and at 1.5 T in Az values for either reader (P > 0.35). CONCLUSION: 3.0 T MRI is an equivalent imaging modality to 1.5 T imaging for presurgical evaluation of endometrial carcinoma, although not significantly superior to 1.5 T imaging.

Effect of superparamagnetic iron oxide on tumor-to-liver contrast at T2*-weighted gradient-echo MRI: comparison between 3.0T and 1.5T MR systems.

PURPOSE: To compare 3.0T and 1.5T MR systems in terms of the effect of superparamagnetic iron oxide (SPIO) on tumor-to-liver contrast in T2*-weighted gradient-echo MRI. MATERIALS AND METHODS: SPIO-enhanced gradient-echo MR images of the liver with four different TEs (3, 5.3, 6.5, and 8.5 msec) were obtained by means of 1.5T and 3.0T systems. Quantitative analyses of relative signal intensities (SIs) and relative tumor contrast and qualitative analyses of image quality and lesion conspicuity of the liver were performed in 22 patients, 16 of whom had malignant liver tumors. RESULTS: With both 1.5T and 3.0T, at TE=8.4 msec, the relative SI of liver and relative tumor contrast were significantly (P<0.01) lower and higher, respectively, than that for any of the other TEs. There were no significant differences in the relative SI of the liver, relative tumor contrast, image quality, and tumor conspicuity for the same TE between the 1.5T and 3.0T systems. CONCLUSION: Our results showed that the effect of SPIO on tumor-to-liver contrast at T2*-weighted gradient-echo imaging was similar for the 1.5T and 3.0T systems, and that the 8.4-msec TE was optimal of the four TEs used in this study at 3.0T.

64-slice multidetector row computed tomographic angiography of aortoiliac and lower extremity arteries: efficacy of test injection using a monitoring scan at knee level.

OBJECTIVES: To evaluate the efficacy of test injection technique using a monitoring scan at knee level for 64-slice multidetector row computed tomographic (MDCT) angiography of the abdominal and lower extremity arteries. METHODS: The test injection technique using low-dose serial CT scan at knee level was performed for 58 patients. Time elapsed from contrast material injection to peak enhancement for the popliteal arteries was applied to scan delay for CT angiography. 64-Slice MDCT angiography of the abdominal and lower extremity arteries obtained with a table speed of 137.5 mm/s was evaluated. RESULTS: The time to peak enhancement was unavailable in 2 cases. CT angiographic images were of good quality in 54 cases, whereas prominent enhancement of abdominal veins was observed in 2 cases. CONCLUSIONS: The test injection using a monitoring scan at knee level was found to be useful for 64-slice MDCT angiography of the abdominal and lower extremity arteries.

Uterine cervical carcinoma: preoperative staging with 3.0-T MR imaging--comparison with 1.5-T MR imaging.

PURPOSE: To prospectively evaluate the efficacy of 3.0-T magnetic resonance (MR) imaging in the preoperative staging of cervical carcinoma compared with that at 1.5-T imaging, with surgery and pathologic analysis as the reference standards. MATERIALS AND METHODS: Institutional review board approval and informed consent were obtained. Thirty-one consecutive patients (age range, 27-71 years; mean age, 51.1 years) underwent 3.0- and 1.5-T MR imaging. Quantitative and qualitative analyses were performed. Two radiologists independently evaluated images in terms of local-regional staging. MR findings were compared with surgicopathologic findings. RESULTS: Mean tumor signal-to-noise ratios, mean cervical stroma signal-to-noise ratios, and mean tumor-to-cervical stroma contrast-to-noise ratios at 3.0-T imaging were significantly higher than those at 1.5-T imaging (P = 9.1 x 10(-6), P = 1.8 x 10(-6), and P = .008, respectively). Image homogeneity at 3.0-T imaging was significantly inferior to that at 1.5-T imaging (P = .005). There were no significant differences in terms of the degree of susceptibility artifacts. Interobserver agreement between the two radiologists for local-regional staging was good or excellent (kappa = 0.65-0.89). Sensitivity, specificity, and area under the receiver operating characteristic curve for radiologist 1 in the evaluation of parametrial invasion were (a) 75% for both 3.0- and 1.5-T imaging, (b) 70% for both 3.0- and 1.5-T imaging, and (c) 0.82 for 3.0-T imaging and 0.85 for 1.5-T imaging, respectively. Corresponding values for vaginal invasion were (a) 67% for both 3.0- and 1.5-T imaging, (b) 68% for 3.0-T imaging and 72% for 1.5-T imaging, and (c) 0.62 for 3.0-T imaging and 0.67 for 1.5-T imaging, respectively. Corresponding values for lymph node metastases were (a) 57% for both 3.0- and 1.5-T imaging, (b) 83% for 3.0-T imaging and 88% for 1.5-T imaging, and (c) 0.72 for 3.0-T imaging and 0.78 for 1.5-T imaging, respectively. Neither radiologist noted significant differences between values obtained with 3.0-T imaging and those obtained with 1.5-T imaging (P > .5 for all comparison pairs). CONCLUSION: In this study, 3.0-T MR imaging was characterized by high diagnostic accuracy in the presurgical evaluation of patients with cervical carcinoma, although 3.0-T imaging was not significantly superior to 1.5-T imaging.

Bland embolization of hepatocellular carcinoma using superabsorbent polymer microspheres.

The purpose of this study was to investigate the clinical outcomes of bland embolization using superabsorbent polymer microspheres (SAP-TAE) as an initial therapeutic option for previously untreated hepatocellular carcinoma (HCC) ineligible for resection or ablation. Fifty-nine patients with previously untreated HCC unamenable to surgery or ablation underwent bland embolization using 100- to 200-mum reconstituted SAP particles (SAP-TAE) as the initial treatment. SAP-TAE was repeated as needed based on tumor response but was switched to chemoembolization when necessary to control residual or progressive tumor. Early tumor response was assessed by contrast-enhanced CT according to RECIST and EASL criteria 1 month after the initial SAP-TAE. The overall survival was calculated using the Kaplan-Meier method. The overall mean follow-up period was 30.6 months (range, 7-59 months). A total of 121 sessions of SAP-TAE were performed, with 1-5 sessions per patient (mean, 2.1 sessions). The mean period of repeated SAP-TAE was 15.6 months (range, 1-51 months), and it exceeded 1 and 2 years in 32 (54%) and 15 (25%) patients, respectively. Thirteen (22%) patients underwent repeated SAP-TAE alone, and the remaining 46 (78%) patients underwent subsequent chemoembolization. No major complication was observed and postembolization syndrome was minimal after SAP-TAE in all patients. Response rate was 14% and 66% by RECIST and EASL criteria, respectively. Overall survival rates were 100% and 83% at 1 and 2 years, respectively, and median survival time was 30 months. In conclusion, SAP-TAE was a safe and repeatable option as the induction therapy for HCC unamenable to surgery or ablation, despite the high incidence of converting to TACE during the total course.